Nan Fung Trinity HK Ltd. Acquires 151,883 Shares of Zai Lab Limited Unsponsored ADR $ZLAB

Nan Fung Trinity HK Ltd. raised its holdings in shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) by 106.9% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 293,966 shares of the company’s stock after acquiring an additional 151,883 shares during the quarter. Nan Fung Trinity HK Ltd. owned approximately 0.26% of Zai Lab worth $7,743,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Zai Lab in the third quarter worth about $62,000. Nykredit A S bought a new stake in Zai Lab during the 2nd quarter valued at approximately $79,000. China Universal Asset Management Co. Ltd. bought a new stake in Zai Lab during the 3rd quarter valued at approximately $211,000. WealthPlan Investment Management LLC purchased a new position in Zai Lab in the 3rd quarter worth approximately $969,000. Finally, Alps Advisors Inc. lifted its holdings in Zai Lab by 34.9% in the 3rd quarter. Alps Advisors Inc. now owns 148,993 shares of the company’s stock worth $3,924,000 after purchasing an additional 38,562 shares in the last quarter. 41.65% of the stock is currently owned by hedge funds and other institutional investors.

Zai Lab Stock Down 1.4%

Shares of ZLAB stock opened at $26.04 on Friday. Zai Lab Limited Unsponsored ADR has a 12-month low of $15.96 and a 12-month high of $29.02. The stock’s 50-day moving average price is $24.66 and its 200-day moving average price is $21.22.

Zai Lab (NASDAQ:ZLAB) last released its quarterly earnings results on Thursday, November 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.18. Zai Lab had a negative net margin of 44.91% and a negative return on equity of 31.15%. The company had revenue of $108.21 million for the quarter, compared to the consensus estimate of $107.90 million. Equities research analysts predict that Zai Lab Limited Unsponsored ADR will post -2.19 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on ZLAB shares. Weiss Ratings restated a “sell (d-)” rating on shares of Zai Lab in a research note on Tuesday, October 27th. Citigroup lifted their price objective on shares of Zai Lab from $44.00 to $45.00 and gave the company a “buy” rating in a research report on Friday, August 7th. Wall Street Zen raised shares of Zai Lab from a “sell” rating to a “hold” rating in a report on Saturday, September 26th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Zai Lab in a research report on Tuesday, October 6th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $37.25.

Zai Lab Company Profile

Zai Lab is a biopharmaceutical company that discovers, develops and commercializes medicines for patients with serious diseases. Its research and development programs focus on oncology, immunology, neuroscience and infectious diseases. Founded in 2014 by biopharmaceutical executive Samantha Du, the company is headquartered in Shanghai and operates in China and the United States. It advances its own drug candidates and works with international partners to develop and bring therapies to market. Zai Lab’s portfolio includes medicines and development programs for cancers and other conditions, including therapies introduced through licensing and collaboration agreements.